Literature DB >> 22054892

Gene therapy for lung neoplasms.

Anil Vachani1, Edmund Moon, Elliot Wakeam, Andrew R Haas, Daniel H Sterman, Steven M Albelda.   

Abstract

Both advanced-stage lung cancer and malignant pleural mesothelioma are associated with a poor prognosis. Advances in treatment regimens for both diseases have had only a modest effect on their progressive course. Gene therapy for thoracic malignancies represents a novel therapeutic approach and has been evaluated in several clinical trials. Strategies have included induction of apoptosis, tumor suppressor gene replacement, suicide gene expression, cytokine-based therapy, various vaccination approaches, and adoptive transfer of modified immune cells. This review considers the clinical results, limitations, and future directions of gene therapy trials for thoracic malignancies. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22054892      PMCID: PMC3210443          DOI: 10.1016/j.ccm.2011.08.006

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  84 in total

Review 1.  Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers.

Authors:  Zhaohui Peng
Journal:  Hum Gene Ther       Date:  2005-09       Impact factor: 5.695

2.  Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer.

Authors:  Toshiyoshi Fujiwara; Noriaki Tanaka; Susumu Kanazawa; Shoichiro Ohtani; Yasuo Saijo; Toshihiro Nukiwa; Kunihiko Yoshimura; Tetsuo Sato; Yoshikatsu Eto; Sunil Chada; Haruhiko Nakamura; Harubumi Kato
Journal:  J Clin Oncol       Date:  2006-02-27       Impact factor: 44.544

3.  Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.

Authors:  Paul Ritch; Charles M Rudin; Jacob David Bitran; Martin J Edelman; Alex Makalinao; David Irwin; Rogerio Lilenbaum; Patrick Peterson; William J John
Journal:  Lung Cancer       Date:  2006-02-28       Impact factor: 5.705

4.  [Clinical research on recombinant human Ad-p53 injection combined with cisplatin in treatment of malignant pleural effusion induced by lung cancer].

Authors:  Wei-Zhu Zhao; Ji-Kun Wang; Wei Li; Xiu-Li Zhang
Journal:  Ai Zheng       Date:  2009-12

5.  Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.

Authors:  J Nemunaitis; M Nemunaitis; N Senzer; P Snitz; C Bedell; P Kumar; B Pappen; P B Maples; D Shawler; H Fakhrai
Journal:  Cancer Gene Ther       Date:  2009-03-13       Impact factor: 5.987

6.  Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.

Authors:  Luis Paz-Ares; Jean-Yves Douillard; Piotr Koralewski; Christian Manegold; Egbert F Smit; José Miguel Reyes; Gee-Chen Chang; William J John; Patrick M Peterson; Coleman K Obasaju; Michael Lahn; David R Gandara
Journal:  J Clin Oncol       Date:  2006-03-20       Impact factor: 44.544

7.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

Authors:  Carmine Carpenito; Michael C Milone; Raffit Hassan; Jacqueline C Simonet; Mehdi Lakhal; Megan M Suhoski; Angel Varela-Rohena; Kathleen M Haines; Daniel F Heitjan; Steven M Albelda; Richard G Carroll; James L Riley; Ira Pastan; Carl H June
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-11       Impact factor: 11.205

Review 8.  Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.

Authors:  David H Kirn; Steve H Thorne
Journal:  Nat Rev Cancer       Date:  2009-01       Impact factor: 60.716

9.  Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up.

Authors:  Yong-song Guan; Yuan Liu; Qing Zou; Qing He; Zi La; Lin Yang; Ying Hu
Journal:  J Zhejiang Univ Sci B       Date:  2009-05       Impact factor: 3.066

10.  Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.

Authors:  David A Garber; Leigh A O'Mara; Jun Zhao; Sailaja Gangadhara; InChul An; Mark B Feinberg
Journal:  PLoS One       Date:  2009-05-06       Impact factor: 3.240

View more
  6 in total

1.  Overexpression of MCPH1 inhibits uncontrolled cell growth by promoting cell apoptosis and arresting the cell cycle in S and G2/M phase in lung cancer cells.

Authors:  Limin Zhou; Yanjie Bai; Yanxi Li; Xueliang Liu; Tao Tan; Shasha Meng; Wenting He; Xiaobin Wu; Zhifang Dong
Journal:  Oncol Lett       Date:  2015-11-04       Impact factor: 2.967

2.  Suicide Gene Therapy for Cancer - Current Strategies.

Authors:  Paul Zarogoulidis; Kaid Darwiche; Antonios Sakkas; Lonny Yarmus; Haidong Huang; Qiang Li; Lutz Freitag; Konstantinos Zarogoulidis; Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2013-08-09

3.  Natural diterpenes from coffee, cafestol and kahweol induce apoptosis through regulation of specificity protein 1 expression in human malignant pleural mesothelioma.

Authors:  Kyung-Ae Lee; Jung-Il Chae; Jung-Hyun Shim
Journal:  J Biomed Sci       Date:  2012-06-26       Impact factor: 8.410

4.  Safety and efficacy of suicide gene therapy with adenosine deaminase 5-fluorocytosine silmutaneously in in vitro cultures of melanoma and retinal cell lines.

Authors:  Antonios Sakkas; Paul Zarogoulidis; Kalliopi Domvri; Wolfgang Hohenforst-Schmidt; Dimitris Bougiouklis; Stylianos Kakolyris; Thomas Zarampoukas; Ioannis Kioumis; Georgia Pitsiou; Haidong Huang; Qiang Li; Soultana Meditskou; Theodora Tsiouda; Nikolaos Pezirkianidis; Konstantinos Zarogoulidis
Journal:  J Cancer       Date:  2014-04-17       Impact factor: 4.207

5.  Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer.

Authors:  Irina V Alekseenko; Eugene V Snezhkov; Igor P Chernov; Victor V Pleshkan; Victor K Potapov; Alexander V Sass; Galina S Monastyrskaya; Eugene P Kopantzev; Tatyana V Vinogradova; Yuri V Khramtsov; Alexey V Ulasov; Andrey A Rosenkranz; Alexander S Sobolev; Olga A Bezborodova; Anna D Plyutinskaya; Elena R Nemtsova; Raisa I Yakubovskaya; Eugene D Sverdlov
Journal:  J Transl Med       Date:  2015-03-04       Impact factor: 5.531

6.  MEN1 gene replacement therapy reduces proliferation rates in a mouse model of pituitary adenomas.

Authors:  Gerard V Walls; Manuel C Lemos; Mahsa Javid; Miriam Bazan-Peregrino; Jeshmi Jeyabalan; Anita A C Reed; Brian Harding; Damian J Tyler; Daniel J Stuckey; Sian Piret; Paul T Christie; Olaf Ansorge; Kieran Clarke; Len Seymour; Rajesh V Thakker
Journal:  Cancer Res       Date:  2012-08-21       Impact factor: 12.701

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.